Literature DB >> 29700091

Diagnosis and treatment of severe asthma: a phenotype-based approach.

Thomas L Jones1, Daniel M Neville2, Anoop J Chauhan2.   

Abstract

Severe asthma is a heterogeneous and often difficult to treat condition that results in a disproportionate cost to healthcare systems. Appropriate diagnosis and management of severe asthma is critical, as most asthma deaths have been retrospectively identified as having poorly recognised severe asthma. With multiple biologic agents becoming available, it is crucial to correctly phenotype patients in order to identify those that will respond to these high-cost treatments. We provide an overview of the assessment, phenotyping and management of severe asthma in primary and secondary care. © Royal College of Physicians 2018. All rights reserved.

Entities:  

Keywords:  Assessment; asthma; phenotyping; treatment

Mesh:

Year:  2018        PMID: 29700091      PMCID: PMC6334025          DOI: 10.7861/clinmedicine.18-2-s36

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  28 in total

Review 1.  Written action plans for asthma: an evidence-based review of the key components.

Authors:  P G Gibson; H Powell
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

2.  Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.

Authors:  Wendy C Moore; Eugene R Bleecker; Douglas Curran-Everett; Serpil C Erzurum; Bill T Ameredes; Leonard Bacharier; William J Calhoun; Mario Castro; Kian Fan Chung; Melissa P Clark; Raed A Dweik; Anne M Fitzpatrick; Benjamin Gaston; Mark Hew; Iftikhar Hussain; Nizar N Jarjour; Elliot Israel; Bruce D Levy; James R Murphy; Stephen P Peters; W Gerald Teague; Deborah A Meyers; William W Busse; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2007-02       Impact factor: 10.793

3.  Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.

Authors:  William W Busse; Stephen Holgate; Edward Kerwin; Yun Chon; Jingyuan Feng; Joseph Lin; Shao-Lee Lin
Journal:  Am J Respir Crit Care Med       Date:  2013-12-01       Impact factor: 21.405

4.  The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry.

Authors:  Stephen O'Neill; Joan Sweeney; Chris C Patterson; Andrew Menzies-Gow; Rob Niven; Adel H Mansur; Christine Bucknall; Rekha Chaudhuri; Neil C Thomson; Chris E Brightling; Ciaran O'Neill; Liam G Heaney
Journal:  Thorax       Date:  2014-06-10       Impact factor: 9.139

Review 5.  Cyclosporin as an oral corticosteroid sparing agent in stable asthma.

Authors:  D J Evans; P Cullinan; D M Geddes
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 6.  The link between fungi and severe asthma: a summary of the evidence.

Authors:  D W Denning; B R O'Driscoll; C M Hogaboam; P Bowyer; R M Niven
Journal:  Eur Respir J       Date:  2006-03       Impact factor: 16.671

7.  Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial.

Authors:  Guy G Brusselle; Christine Vanderstichele; Paul Jordens; René Deman; Hans Slabbynck; Veerle Ringoet; Geert Verleden; Ingel K Demedts; Katia Verhamme; Anja Delporte; Bénédicte Demeyere; Geert Claeys; Jerina Boelens; Elizaveta Padalko; Johny Verschakelen; Georges Van Maele; Ellen Deschepper; Guy F P Joos
Journal:  Thorax       Date:  2013-01-03       Impact factor: 9.139

Review 8.  Antifungals in severe asthma.

Authors:  Amit D Parulekar; Zuzana Diamant; Nicola A Hanania
Journal:  Curr Opin Pulm Med       Date:  2015-01       Impact factor: 3.155

Review 9.  Bronchial thermoplasty for moderate or severe persistent asthma in adults.

Authors:  Alfons Torrego; Ivan Solà; Ana Maria Munoz; Marta Roqué I Figuls; Juan Jose Yepes-Nuñez; Pablo Alonso-Coello; Vicente Plaza
Journal:  Cochrane Database Syst Rev       Date:  2014-03-03

Review 10.  IL-17 in severe asthma. Where do we stand?

Authors:  Julie Chesné; Faouzi Braza; Guillaume Mahay; Sophie Brouard; Marc Aronica; Antoine Magnan
Journal:  Am J Respir Crit Care Med       Date:  2014-11-15       Impact factor: 21.405

View more
  7 in total

Review 1.  The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19.

Authors:  Iphigenia Gintoni; Maria Adamopoulou; Christos Yapijakis
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

2.  Leukocytes in Critical Patients With Asthma Exacerbation.

Authors:  Hussein Rabah; Ahmad Itani; Michel Chalhoub
Journal:  Cureus       Date:  2021-12-19

3.  Patients with Severe Uncontrolled Asthma: Perception of Asthma Control and its Management.

Authors:  Maureen George; Camille Graff; Alexis Bombezin-Domino; Emilie Pain
Journal:  Pulm Ther       Date:  2022-04-26

Review 4.  Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.

Authors:  Peter G Gibson; Charlene M Prazma; Geoffrey L Chupp; Eric S Bradford; Mark Forshag; Stephen A Mallett; Steve W Yancey; Steven G Smith; Elisabeth H Bel
Journal:  Respir Res       Date:  2021-06-07

5.  Silencing of circHIPK3 hampers platelet-derived growth factor-induced proliferation and migration in airway smooth muscle cells through the miR-375/MMP-16 axis.

Authors:  Yu Jiang; Xiaoqing Guo; Junhong Qin
Journal:  Cytotechnology       Date:  2021-07-04       Impact factor: 2.040

Review 6.  Diabetes and Lung Disease: A Neglected Relationship.

Authors:  Jasmin Khateeb; Eyal Fuchs; Mogher Khamaisi
Journal:  Rev Diabet Stud       Date:  2019-02-25

7.  Myrcene exerts anti-asthmatic activity in neonatal rats via modulating the matrix remodeling.

Authors:  Yanhui Du; Jie Luan; Ren Peng Jiang; Juan Liu; Yan Ma
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.